Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AERO-111
- Development stage
- Preclinical
- Lead developer
- AeroRx Therapeutics
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
AERO-111 is an IND-enabling, proprietary nebulized small-molecule triple-combination therapy being developed by AeroRx for chronic obstructive pulmonary disease. It combines a long-acting beta-2 adrenergic receptor agonist, a long-acting muscarinic M3 receptor antagonist, and an inhaled corticosteroid intended for patients who require escalation beyond dual bronchodilator therapy. The specific active ingredients have not been publicly disclosed.
- Other names
- Aero 111Aero111Aero-111
02
Targets
GR (Glucocorticoid receptor)CHRM3 (M3)ADRB2 (β2)
Beyond the preview
Go deeper on AERO-111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AERO-111.